Core Viewpoint - The announcement of a potential change in control at Asia-Pacific Pharmaceutical has attracted market attention, particularly given the company's history of six consecutive years of net profit losses excluding non-recurring items [1][2]. Group 1: Financial Performance - Asia-Pacific Pharmaceutical has reported net profit losses excluding non-recurring items for six consecutive years from 2019 to 2024, with losses of -1.94 billion, -143 million, -239 million, -117 million, -68.94 million, and -28.13 million respectively [1]. - Although the company has shown a reduction in losses from 2022 to 2024, it has not yet returned to profitability [1]. Group 2: Regulatory Issues - The company has faced multiple regulatory challenges, including receiving inquiry letters from the Shenzhen Stock Exchange regarding its financial performance and cash flow from 2019 to 2022 [2]. - In April 2021, the Zhejiang Securities Regulatory Bureau issued an administrative penalty against the company for false financial reporting from 2016 to 2018, resulting in a five-year market ban for the then-chairman and general manager [2]. - The company has also received warnings and public reprimands from the Shenzhen Stock Exchange during the 2020 to 2022 period [2]. Group 3: Control Change Significance - The planned change in control is seen as a critical opportunity for the company to seek new development avenues and improve its operational status [2]. - A new controlling shareholder may bring in a new management team and strategic planning, potentially enhancing corporate governance, operational efficiency, and market expansion [2]. - However, uncertainties remain regarding whether the new controlling shareholder can effectively address existing operational issues and enhance the company's competitive edge in a challenging market [2][3].

Core Viewpoint - Three listed companies, Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced on the same day that they are planning changes in control, which may lead to changes in their controlling shareholders and actual controllers [1] Group 1: Duori Pharmaceutical - Duori Pharmaceutical's major shareholder, Tibet Jiakang Times Technology Development Co., is planning a change in control, which may lead to a change in the company's controlling shareholder and actual controller [2] - The company has experienced continuous revenue decline from 2022 to 2024, which may be a reason for the planned change in control [2] - Duori Pharmaceutical's revenue for the first half of 2025 was 107 million yuan, a year-on-year decline of 29.13%, with a net loss of 42.5 million yuan, compared to a loss of 3.27 million yuan in the same period last year [3] Group 2: Asia-Pacific Pharmaceutical - Asia-Pacific Pharmaceutical's major shareholder, Ningbo Fubang Holdings Group, is also planning a change in control, with specific transaction plans and agreements still under discussion [4] - The company has faced continuous revenue decline, with a net profit of -48.86 million yuan for the first half of 2025, a year-on-year decrease of 524.31% [5] - Asia-Pacific Pharmaceutical's revenue for the first half of 2025 was 152 million yuan, a year-on-year decrease of 31.48%, attributed to centralized procurement and intensified market competition [5]

Group 1 - The core point of the article is that Zhejiang Yatai Pharmaceutical Co., Ltd. is planning a change in company control, leading to a suspension of its stock trading [1] - The company received a notification on September 26 from its controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., and associated parties regarding the control change [1] - The stock suspension will take effect on September 29, 2025, and is expected to last no more than two trading days [1]

Group 1: Control Change Announcements - Multiple A-share companies, including Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced plans for control change on September 28 [1] - Duori Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and actual controller Deng Yong are planning a change in control, leading to a suspension of trading from September 29, 2025, for up to two trading days [3] - Asia-Pacific Pharmaceutical received notification from its controlling shareholder, Ningbo Fubang Holdings Group Co., Ltd., regarding a potential change in control, with trading suspended from September 29, 2025, for up to two trading days [5] - Zhonghuan Environmental Protection's controlling shareholder, Zhang Bozhong, is also planning a control change, resulting in trading suspension from September 29, 2025, for up to two trading days [7] Group 2: Specific Company Details - Duori Pharmaceutical's stock was suspended at a price of 40.08, with a market capitalization of 3.206 billion [2] - Asia-Pacific Pharmaceutical's stock was suspended at a price of 5.67, with a market capitalization of 4.228 billion [4] - Zhonghuan Environmental Protection's stock was suspended at a price of 8.86, with a market capitalization of 3.761 billion [6]

（责任编辑：蔡情） 公司于2025年9月26日收到控股股东宁波富邦控股集团有限公司及一致行动人上海汉贵投资管理有 限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及一致行动人宋凌杰的通知，其正在筹划公 司控制权变更事项，具体交易方案、协议条款等尚需进一步论证和磋商，目前相关各方尚未签署正式交 易协议。具体情况届时以各方签订的相关正式交易协议为准。 上述事项可能导致公司控股股东及实际控制人发生变更。鉴于上述事项处于筹划阶段，尚存在重大 不确定性，为保证公平信息披露，避免公司股价异常波动，维护广大投资者利益，经公司向深圳证券交 易所申请，公司股票（证券简称：亚太药业，证券代码：002370）自2025年9月29日（星期一）开市起 停牌，预计停牌时间不超过2个交易日。 中国经济网北京9月29日讯 亚太药业(002370.SZ)昨晚披露了关于筹划公司控制权变更事项的停牌公 告。 ...

编辑 王进雨 新京报贝壳财经讯 9月28日，亚太药业公告称，公司于2025年9月26日收到控股股东宁波富邦控股集团 有限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队 及一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一步 论证和磋商。 为保证公平信息披露，避免公司股价异常波动，公司股票自2025年9月29日起停牌，预计停牌时间不超 过2个交易日。停牌期间，公司将根据相关事项进展情况，履行信息披露义务。 ...

Core Viewpoint - Three A-share listed companies, Duori Pharmaceutical, Zhonghuan Environmental Protection, and Yatai Pharmaceutical, announced plans for changes in control, leading to stock suspension starting September 29, 2025 [1][2]. Company Summaries Duori Pharmaceutical - The controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and actual controller, Mr. Deng Yong, are planning a change in control, which may lead to a change in the controlling shareholder and actual controller [1]. - For the first half of the year, Duori Pharmaceutical reported revenue of approximately 107 million yuan, a year-on-year decrease of 29.13%, and a net profit attributable to shareholders of -42.5 million yuan, compared to -3.27 million yuan in the same period last year [4]. Zhonghuan Environmental Protection - The controlling shareholder, Mr. Zhang Bozhong, and his concerted party, Anhui Zhongchen Investment Holding Co., Ltd., are also planning a change in control [1]. - In the first half of the year, Zhonghuan Environmental Protection achieved total revenue of 474 million yuan, a year-on-year increase of 4.84%, and a net profit attributable to shareholders of 44.1 million yuan, up 9.69% [4]. Yatai Pharmaceutical - The controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., and the management team are planning a change in control, with further discussions needed on the specific transaction plan and agreement terms [1]. - Yatai Pharmaceutical's stock price closed at 5.67 yuan per share on September 26, 2025, with a year-to-date market value increase of 85.9% [3]. - The company reported revenue of approximately 152 million yuan for the first half of the year, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders was approximately 105 million yuan, a significant increase of 1820.97%. However, the non-recurring net profit was -48.86 million yuan [3][4].

Group 1: Control Change Announcements - Multiple A-share companies, including Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced plans for control changes on September 28 [1][3][4] - Duori Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., is planning a control change, leading to a potential change in the actual controller [1] - Asia-Pacific Pharmaceutical's controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., is also planning a control change, with no formal agreement signed yet [3] - Zhonghuan Environmental Protection's controlling shareholder, Zhang Bozhong, is in the process of planning a control change, which may affect the actual controller [4] Group 2: Company Profiles and Operations - Duori Pharmaceutical specializes in the R&D, production, and sales of chemical drug formulations and intermediates, with leading market share in products like Acetate Sodium Ringer Injection [1] - Asia-Pacific Pharmaceutical focuses on pharmaceutical manufacturing, including the R&D and sales of chemical formulations, with a portfolio of 114 approved formulations [3] - Zhonghuan Environmental Protection is a national high-tech enterprise engaged in water environment governance and waste treatment, providing comprehensive solutions in various segments [5] - Guanzhong Ecology is undergoing a control change with a share transfer agreement to Deep Blue Whale, which will result in a new controlling shareholder [7]

亚太药业（002370）(002370.SZ)公告，公司于2025年9月26日收到控股股东宁波富邦（600768）控股集 团有限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团 队及一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一 步论证和磋商，目前相关各方尚未签署正式交易协议。公司股票自2025年9月29日开市起停牌，预计停 牌时间不超过2个交易日。 ...

智通财经APP讯，亚太药业(002370.SZ)公告，公司于2025年9月26日收到控股股东宁波富邦控股集团有 限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及 一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一步论 证和磋商，目前相关各方尚未签署正式交易协议。公司股票自2025年9月29日开市起停牌，预计停牌时 间不超过2个交易日。 ...